Compare First Citizens BancShares Inc (FCNCA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? First Citizens BancShares Inc trades at $2,052.8 (market cap $22.80B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: First Citizens BancShares Inc is far larger — about 4.7× Travere Therapeutics Inc. Common Stock's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 30 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FCNCA | TVTX | |
|---|---|---|
Market Cap | $22.80B | $4.88B |
Volume | 44,337 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $67.52 |
52-Week Low | $1.64K | $26.79 |
Typical Hold Time | 30 Days | 0 Days |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCNCA trades at $2,075.12, down 0.35% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $57.09 per share, beating estimates, and maintains a net income margin of 25.23%. Recent news includes a $157 million financing deal and branch expansion initiatives, signaling growth. Cash flow improved to a net positive $630 million in 2026 from a slight deficit in 2025.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but technical bearishness and high institutional hold ratings suggest near-term caution. Key risks include execution of expansion and interest rate sensitivity. The stock offers value with a P/E of 11.13, yet requires monitoring of technical levels for entry.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
